EP1904176A1 - Procedes permettant d'exfolier la peau et d'augmenter le renouvellement de celle-ci au moyen d'un rayonnement pulse intense a fluidite elevee - Google Patents

Procedes permettant d'exfolier la peau et d'augmenter le renouvellement de celle-ci au moyen d'un rayonnement pulse intense a fluidite elevee

Info

Publication number
EP1904176A1
EP1904176A1 EP06753536A EP06753536A EP1904176A1 EP 1904176 A1 EP1904176 A1 EP 1904176A1 EP 06753536 A EP06753536 A EP 06753536A EP 06753536 A EP06753536 A EP 06753536A EP 1904176 A1 EP1904176 A1 EP 1904176A1
Authority
EP
European Patent Office
Prior art keywords
fluency
skin
pulsed light
intense pulsed
light source
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06753536A
Other languages
German (de)
English (en)
Inventor
Careen A. Schroeter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1904176A1 publication Critical patent/EP1904176A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
    • A61B18/203—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser applying laser energy to the outside of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00452—Skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00452—Skin
    • A61B2018/0047—Upper parts of the skin, e.g. skin peeling or treatment of wrinkles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B2018/1807—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using light other than laser radiation

Definitions

  • Light therapy is an emerging field, wherein light emitting diodes and other emitters of electromagnetic radiation are used to treat various medical conditions such as acne, hair growth stimulation, hair growth inhibition, scar reduction and removal, wrinkle reduction, etc.
  • Dermabrasion, chemical peeling, and laser and flashlamp skin resurfacing have been established to attain their therapeutic effects by stimulating a wound-healing response that leads to an increase in dermal collagen (Tsai, et al . (1995) Dermatol. Surg. 21:539-4; Nelson, et al . (1995) J. Am. Acad. Dermatol. 32:472-8; Menaker, et al. (1999) Dermatol. Surg. 25:440-4; Fournier, et al . (2001) Dermatol. Surg. 27:799-806; Goldberg and Cutler (2000) Lasers Surg. Med. 26:196-200; Zelickson and Kist (2000) Lasers Surg. Med. 12:17) .
  • the nonablative laser is able to generate dermal temperature increase of 30-40 0 C while limiting thermal injury to the epidermis (Lask, et al. (1997) SPIE Proc . 2970:338-49).
  • the dermal heat may eventually result in activation of fibroblasts to produce a long term healing response and subsequent collagen remodeling (Lask, et al . (1997) supra; Fitzpatrick, et al . (1996) Arch. Dermatol. 132:395-405).
  • Shorter wavelength technologies have been hypothesized to induce a heat-mediated cytokine activation (Goldberg (2000) J. Cutan. Laser Ther. 2:59-61).
  • U.S. Patent Application Serial No. 10/119,772 describes the manipulation of collagen, fibroblast, and fibroblast-derived cell levels in mammalian tissue using a plurality of pulses from at least one source of narrowband, multichromatic electromagnetic radiation (e.g., from a light emitting diode, a laser, a fluorescent light source, an organic light emitting diode, a light emitting polymer, a xenon arc lamp, a metal halide lamp, a filamentous light source, an intense pulsed light source, a sulfur lamp, and combinations thereof) having a dominant emissive wavelength of from about 300 nm to about 1600 nm, and wherein said pulses have a duration of from about 0.1 femtoseconds to about 100 seconds, the interpulse delay between said pulses is from about 0.1 to about 1000 milliseconds, and the energy fluence received by said tissue is less than about 10 joule per square centimeter.
  • the present invention is a method for increasing the proliferation or turnover of at least one layer of skin by exposing skin to a high-fluency, intense pulsed light source.
  • the present invention is also a method for stimulating sloughing of the stratum corneum of the epidermis by exposing skin to a high-fluency, intense pulsed light source .
  • Figure 1 illustrates the relative expression of TN and TGF- ⁇ in the follicular bulb (Figure IA) , germinative epidermis (Figure IB) and in plasma cells (Figure 1C) up to approximately 4 months after treatment with an intense pulsed light source.
  • a high-fluency, intense pulsed light source can induce the expression of TGF- ⁇ in skin cells, resulting in the release of extracellular matrix proteins such as tenascin, and an increase in the concentration of fibroblasts and plasma cells. Further, increased expression of Ki67 is observed in both dermal and epidermal layers, indicative of increased proliferation of these skin cells.
  • the high-fluency, intense pulsed light source methodology disclosed herein produces an artificial wound (i.e., not occurring by natural means such as by accident) thereby stimulating the immune system and extracellular matrix formation
  • the present invention relates to the use of a high-fluency intense pulsed light source for dermatologic treatment and plastic surgery treatment.
  • Such dermatologic treatment includes increasing the turnover of at least one layer of human or mammalian skin and stimulating sloughing of the outer layer of the epidermis .
  • pigs were treated with 40 flashes (6.5-21 ms) of light having a wavelength ranging from 565 to 695 nm and a fluency of 35-60 J/cm 2 . With higher fluency, erythema was observed. Using a wavelength of 640 nm, pulse time between 4.2 to 4.8 milliseconds (ms) and energy of 35 J/cm 2 , negligible erythema was observed. While no blisters were identified, hair on the pigs was burnt and transient depigmentation was observed, but disappeared after some time.
  • Biopsy samples taken from the irradiated pigs were stained for the presence of TGF- ⁇ l and tenascin. One day after radiation, the appearance of TGF- ⁇ l in the basal epidermal layer and the follicular bulb was detected.
  • Fibroblasts and plasma cells were also strongly positive. After 1 week, the outermost epidermis, endothelial vessels, follicular bulb, fibroblasts and plasma cells were intensely stained (Figure 1) . TGF- ⁇ l immunoreactivity decreased after 2 weeks, reaching a level similar to that found on the first day of treatment. After one month, the expression of TGF- ⁇ reached a peak value and then began to slowly fall in the second and third month. Subsequently, TGF- ⁇ l levels began to increase and on day 120 elevated levels were observed.
  • the Ki67 protein is expressed in all phases of the cell cycle except GO and serves as a marker for cell proliferation (Schluter, et al . (1993) J. Cell Biol. 123:513-522). Upon exposure to high-fluency, intense pulsed light, both dermal and epidermal layers were found to exhibit an increase in the expression of Ki67, indicative of an increase in cell proliferation.
  • the present invention embraces the use of a high-fluency, intense pulsed light source in a method for increasing the proliferation and turnover of at least one layer of skin in a subject.
  • the skin of the subject is exposed to an effective amount of high-fluency, intense pulsed light so that TGF- ⁇ and Ki67 expression is increased thereby stimulating proliferation and turnover of skin cells.
  • the proliferation and turnover of one or more layers of skin is contemplated.
  • the use of a dominant wavelength emission in the range of about 500 nm will be useful for increasing the proliferation and turnover of epidermal layers of skin, whereas light having a wavelength of about 600 nm to about 660 nm can be used for increasing the proliferation and turnover of epidermal and dermal layers of skin.
  • An effective amount of light in the context of this method of the invention, is an amount which stimulates or increases the turnover of skin, e.g., from 28-30 days as found in a normal human subject to less than 28 days (e.g., 20-25 days) upon exposure to high-fluency, intense pulsed light.
  • Suitable effective amounts or parameters associated with high-fluency, intense pulsed light which achieve the desired effect are disclosed herein and can vary with the desired layers to be treated.
  • the epidermis is composed of many layers including the horny layer (stratum corneum) , the clear layer (stratum lucidum) , granular layer (stratum granulosum) , prickle-cell layer (stratum spinosum) ; and basal layer (stratum basale) .
  • the basal layer of the epidermis new cells are constantly being reproduced, pushing older cells to the surface.
  • skin cells move farther away from their source of nourishment, they flatten and shrink. They lose their nuclei, move out of the basal layer to the stratum corneum which is composed of about 15 to 20 cell layers, and turn into keratin.
  • the present invention is also a method for stimulating sloughing of the stratum corneum of the epidermal layer using an effective amount of high-fluency, intense pulsed light.
  • An effective amount of said light is an amount which results in an increase in the amount or rate of sloughing of stratum corneum cells. For example, an adult human sheds approximately 10 grams of skin cells a day, and therefore an increase in the amount of skin cells sloughed per day would be indicative of high-fluency, intense pulsed light exposure stimulating skin cell sloughing.
  • fluency is defined as the power level of the radiation reaching target tissue.
  • a high-fluency radiation source produces about 3 to 90 joule per square centimeter (J/cm 2 ) of tissue.
  • high-fluency of about 10 to 50 J/cm 2 is employed.
  • high-fluency of about 35 J/cm 2 is employed.
  • any device that emits intense pulsed light in a bandwidth of ⁇ about 100 nanometers around a dominant wavelength can be can be used in accordance with the methods disclosed herein.
  • any intense pulsed light source capable of exposing the target tissue with from about 3 to 90 J/cm 2 of energy in the desired wavelength (generally within the range of from about 435 nm to about 1900 nm) will be able to achieve the desired result.
  • the tissue penetration depth for intact skin may be different than the tissue penetration depth for ulcerated or burned skin and may also be different for skin that has been abraded or enzymatically peeled or that has had at least a portion of the stratum corneum removed.
  • the wavelength used for any particular application can vary.
  • light having a dominant wavelength emission in the range of about 500 nm may be more suitable for exposing epidermal layers of skin as such a short wavelength has limited depth of penetration, whereas light having a wavelength of about 600 nm to about 660 nm can more easily penetrate to a greater depth, if treatment of the lower dermal layers or even deeper is desired. Accordingly, the selection of the dominant wavelength of the radiation emitter is also dependent on the depth of treatment desired. Suitable wavelengths for inducing TGF- ⁇ are in the range of 590 to 690 nm. As a wavelength of 640 nm was found to minimize erythema, a dominant wavelength of 640 nm is particularly suitable for use in the methods of the instant invention.
  • Exposure time is another aspect of intense pulsed light which can vary with the desired effect and the target cell, tissue or organ.
  • pulse lengths can vary from less than one picosecond to several seconds with interpulse intervals of a few picoseconds to a few hundred milliseconds.
  • the pulse length is in the range of 0.1 to 500 milliseconds and the interpulse interval in the range of 20 to 60 milliseconds.
  • pulse durations of from about 4.2 to 4.8 milliseconds with an interpulse interval of about 20 milliseconds are particularly suitable.
  • the number of pulses (also referred to as repetitions or flashes) per treatment can also be varied. For example, large numbers of pulses may be less effective at inducing cell proliferation than a smaller numbers of pulses.
  • a treatment regime can include between 10 and 100 pulses. In particular embodiments, the number of pulses per treatment is in the range of 40. Further, a treatment can be repeated multiple times over a given period of time (e.g., weeks or months) to achieve the desired result.
  • light penetration into the target tissue can be optimized by varying the treatment head of the intense
  • pulsed light source For example, a large spot size diminishes the scattering of the light beam.
  • Treatment head size can vary from 8-10 mm x 20-45 mm.
  • a particularly suitable treatment head is in the range of 8 mm x 34-35 mm.
  • a high- fluency, intense pulsed light source used in accordance with the instant methods has an emissive wavelength of from about 435 nm to about 1900 nm, wherein the pulses have a duration of from about 2 ms to about 30 ms, and the energy fluence received by the tissue is about 3 to 90 joule per square centimeter.
  • Suitable flashlamp systems which can be used for carrying out the methods disclosed herein include, but are not limited to, the IPLTM Quantum, VASCULIGHTTM, and LUMENIS ONETM, PHOTODERM 1 " and EPILIGHTTM systems as well as those disclosed in GB 2,293,648; EP 0 565 331; U.S. Patent No. 5,405,368; and WO 91/15264.
  • the VASCULIGHTTM ESC Medical Systems Ltd., Yokneam, Israel
  • IPLTM Quantum ESC Sharplan, Yokneam, Israel
  • these flashlamps use non-coherent light of a broad-band spectrum in the range of 435-1900 run.
  • cut-off filters e.g., 515, 550, 570, 590, 615, 645, 695, and 795 run
  • the pulse duration ranges between 2-5 ms (VASCULIGHTTM) and 6-26 ms (IPLTM Quantum) .
  • fluence ranges between 3-90 J/cm 2 (VASCULIGHTTM) and 5-45 J/cm 2 (IPLTM Quantum) can be achieved.
  • Other suitable intense pulsed light sources or flashlamps which can be used in accordance with the parameters disclosed herein are well-known to those of skill in the art.
  • a water-containing gel or solution is used between the skin and the intense pulsed light source probe during treatment to facilitate optical coupling of the light and facilitate heat transfer from the epidermis to the gel.
  • the methods of the present invention can be carried out without blistering, significant erythema or damage to the underlying tissues.
  • the methods of the instant invention will be useful for facilitating epidermal renewal in subjects with acne, large pores, age spots, sun-damaged skin, burns, etc.
  • the methods of the present invention will also be useful in the treatment of psoriasis, eczema
  • neurodemitis neurodemitis
  • viral warts precancerous solar keratosis or skin lesions
  • skin ulcers diabetic, pressure, venous stasis
  • the high- fluency, intense pulsed light source as disclosed herein can be combined, either serially or simultaneously with another light or wavelength source (e.g., laser or radiofrequency) to carry out the methods disclosed herein.
  • the high- fluency, intense pulsed light source and other light or wavelength source can be used together to work synergistically, or combined, wherein each has its own effect.
  • Suitable parameters for radiofrequency include a fluence in the range of about 0.5 J/cm 2 to about 500 J/cm 2 ; a wavelength in the range of about 300 nm to about 1200 nm; a frequency in the range of 500 kHz to 300 MHz; and a spot size in the range of 1 mm 2 to 10 cm 2 .
  • Example 1 Animal Model Male, dark-haired pigs were randomly selected for analysis. An intra muscular injection of Azopyrone (0.5 mg/kg) was administered to initiate anesthesia. The anesthesia was maintained with halothane (3-4%) and nitrous oxide. The back region of the pigs, i.e., between their forelegs and hind legs, and the abdomen was shaved to achieve a maximum penetration depth. The area was washed with hibiscub. Treatment sites were outlined by West Indian ink applied to the skin with hypodermic needles. Four marks outlined a 40 x 20cm 2 treatment area. No ointment was applied pre- or post-operatively in the treatment area. No chemical or mechanical debridement was performed during follow up examinations. Buprenorphine, 0.05-0.1 mg/kg i.p., was given soon after the treatment to minimize pain. The animals were euthanized 120-360 days after treatment using intravenous nembutal (100-150 mg/kg) .
  • a stencil was placed on the back of the pigs to treat the same surface every time.
  • the pigs underwent general anesthesia for 15-30 minutes (5 times for the treatment and 5 times for the biopsies) .
  • a VASCULIGHTTM system with 590 and 695 nm filters and a QUANTUMTM system with 565 and 640 nm filters were used. Pulse times were 6.5 to 21 milliseconds and the fluence was 35 to 60 J/cm 2 .
  • An entire surface of 40 x 2.8 cm 2 was treated per pig.
  • the treatment took 4 to 5 minutes with an interval of 4 weeks between treatments. Treatment regimes are listed in Table 1.
  • Biopsies were performed immediately following light treatment and again on the second, seventh, fourteenth and twenty-eighth post-operative day. In the second month, one week after the last biopsy, the pigs were radiated again and after 3 weeks biopsies were performed. This was continued for four months. A total amount of 240 biopsies were thus taken. Full-thickness, 3-mm punch biopsies were obtained from each treated site. Tissue specimens were fixed in formalin, embedded in paraffin, sectioned and stained with hematoxylin and eosin for light microscopic examination.
  • Pigs were followed daily during the first week. After that they were seen and evaluated after 1, 2, 3, 6, 12, and 30 weeks. They were examined for presence of crust formation, swelling, bleeding, erythema, wound healing, scar formation, depigmentation and loss of hair. Photographs were taken before and after treatment.
  • Tissue blocks of pig skin biopsy were fixed in 4% neutral-buffered paraformaldehyde at 4 0 C for 4 to 12 hours. The specimens were then routinely processed for paraffin embedding at 56°C. Paraffin sections measuring 4 ⁇ m were used for light microscopy and immunohistochemical analysis.
  • Paraffin sections were deparaffinized and rehydrated. Immunohistochemical demonstration of tenascin and TGF- ⁇ antigens was performed on these sections with the avidin- biotin peroxidase (ABC) method. Briefly, these sections were processed through the following incubation steps: hydrogen peroxide 3% in methanol for 30 minutes to block endogenous peroxidase; normal goat serum for TGF- ⁇ l and normal horse serum for tenascin, diluted 1:75 v/v, for 30 minutes to 1 hour to reduce non-specific background staining; incubation with primary antibody anti-TGF- ⁇ l (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and with primary antibody anti-tenascin (Sigma, St Louis, MO) overnight at 4°C; biotinylated secondary goat anti-rabbit IgG (for TGF- ⁇ l ), and horse anti-mouse IgG (for tenascin), diluted 1:200 v/v, for
  • controls included omission of the primary or secondary antibody which resulted in negative staining and the use of human placenta as positive control for tenascin and TGF- ⁇ l antibodies.
  • the data is presented as contingency tables to detect association between technical and clinical parameters.

Landscapes

  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Optics & Photonics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Electromagnetism (AREA)
  • Medical Informatics (AREA)
  • Otolaryngology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'utilisation d'une source lumineuse pulsée intense à fluidité élevée, aux fins d'induction de l'expression de TGF-ß dans des cellules de la peau, une libération de protéines de matrices extracellulaires, telles que la ténascine, et une augmentation de la concentration de fibroblastes et de plasmocytes étant ainsi obtenues. Du fait que la méthodologie de la source lumineuse pulsée intense à fluidité élevée selon l'invention produit une blessure artificielle stimulant le système immunitaire et la formation de matrices extracellulaires, l'invention concerne l'utilisation d'une source lumineuse pulsée intense à fluidité élevée seule ou conjointement avec un traitement au laser ou par radiofréquences pour un traitement dermatologique et un traitement de chirurgie plastique.
EP06753536A 2005-05-09 2006-05-09 Procedes permettant d'exfolier la peau et d'augmenter le renouvellement de celle-ci au moyen d'un rayonnement pulse intense a fluidite elevee Withdrawn EP1904176A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67901505P 2005-05-09 2005-05-09
PCT/EP2006/004339 WO2006119971A1 (fr) 2005-05-09 2006-05-09 Procedes permettant d'exfolier la peau et d'augmenter le renouvellement de celle-ci au moyen d'un rayonnement pulse intense a fluidite elevee

Publications (1)

Publication Number Publication Date
EP1904176A1 true EP1904176A1 (fr) 2008-04-02

Family

ID=36754367

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06753536A Withdrawn EP1904176A1 (fr) 2005-05-09 2006-05-09 Procedes permettant d'exfolier la peau et d'augmenter le renouvellement de celle-ci au moyen d'un rayonnement pulse intense a fluidite elevee

Country Status (2)

Country Link
EP (1) EP1904176A1 (fr)
WO (1) WO2006119971A1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4930504A (en) * 1987-11-13 1990-06-05 Diamantopoulos Costas A Device for biostimulation of tissue and method for treatment of tissue
US5423803A (en) * 1991-10-29 1995-06-13 Thermotrex Corporation Skin surface peeling process using laser
WO1999027863A1 (fr) * 1997-12-04 1999-06-10 Thermolase Corporation Appareil et procede de refroidissement de la peau utilisables dans des traitements cutanes par laser
US6887260B1 (en) * 1998-11-30 2005-05-03 Light Bioscience, Llc Method and apparatus for acne treatment
US6676655B2 (en) * 1998-11-30 2004-01-13 Light Bioscience L.L.C. Low intensity light therapy for the manipulation of fibroblast, and fibroblast-derived mammalian cells and collagen
GB0210302D0 (en) * 2002-05-07 2002-06-12 Siden Ltd Improvements in and relating to intense pulsed light devices
JP2006501960A (ja) * 2002-10-07 2006-01-19 パロマー・メディカル・テクノロジーズ・インコーポレイテッド 光生体刺激を行なうための装置
EP1778355A1 (fr) * 2004-07-16 2007-05-02 JOHNSON & JOHNSON CONSUMER COMPANIES, INC. Traitement de la peau par la lumiere et agent benefique pour attenuer l'acne

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006119971A1 *

Also Published As

Publication number Publication date
WO2006119971A1 (fr) 2006-11-16
WO2006119971A8 (fr) 2007-03-29

Similar Documents

Publication Publication Date Title
Connolly et al. Acne scarring—pathogenesis, evaluation, and treatment options
Fabbrocini et al. Acne scars: pathogenesis, classification and treatment
US6050990A (en) Methods and devices for inhibiting hair growth and related skin treatments
CN103458817A (zh) 用于皮肤激光治疗的装置和方法
Kunzi‐Rapp et al. Minimally invasive skin rejuvenation with Erbium: YAG laser used in thermal mode
KR102405083B1 (ko) 다중 빔 조직 치료를 위한 레이저 시스템
Reed et al. Treatment of periorbital wrinkles
González-Rodríguez et al. Current indications and new applications of intense pulsed light
JP2008523158A (ja) 育毛の低減
Wimmershoff et al. Hair removal using a 5-msec long-pulsed ruby laser
Sawcer et al. Lasers and adjunctive treatments for facial scars: a review
Gamal et al. Updates in surgical treatment of vitiligo
Roosen et al. Temporary hair removal by low fluence photoepilation: histological study on biopsies and cultured human hair follicles
Harto et al. Pulsed dye laser treatment of acne. Study of clinical efficacy and mechanism of action
Kim et al. Picosecond‐domain fractional laser treatment over hyaluronic acid fillers: in vivo and clinical studies
Alora et al. CO2 laser resurfacing of psoriatic plaques: a pilot study
Weir et al. Photo-assisted epilation—review and personal observations
Lyu et al. In vivo and ex vivo skin reactions after multiple pulses of 1,064-nm, microlens array-type, picosecond laser treatment
EP1904176A1 (fr) Procedes permettant d'exfolier la peau et d'augmenter le renouvellement de celle-ci au moyen d'un rayonnement pulse intense a fluidite elevee
Sandel IV et al. CO2 laser resurfacing: still a good treatment
KR101620840B1 (ko) 고출력 프락셔날 레이저 및 고압의 온도를 높인 식염수 분사방식을 이용한 발모 촉진 방법 및 장치
Weijie et al. Intense pulsed light therapy
US20240082279A1 (en) Compositions and methods for preventing and/or treating scars
EP1904177A1 (fr) Methodes de traitement de la peau au moyen d'un rayonnement pulse intense a fluidite elevee
Hedelund et al. CO2 laser resurfacing and photocarcinogenesis: an experimental study

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091201